Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 32.48%, which has investors questioning if this is right time to sell.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp ... for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight ...

Next Step: furnace electrification agreement to use PyroGenesis plasma torches in multi-megawatt industrial processes. MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc ...

Tonix Pharmaceuticals is participating in the Zacks SCR Life Sciences Virtual Investor Forum, which provides an opportunity to engage directly with investors and share insights about the company ...

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp ... for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight ...

CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development ...